Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study
Standard
Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. / Hütter-Krönke, Marie Luise; Fiedler, Walter; Kündgen, Andrea; Krauter, Jürgen; von Lilienfeld-Toal, Marie; Döhner, Hartmut; Schlenk, Richard.
in: HAEMATOLOGICA, Jahrgang 104, Nr. 2, 02.2019, S. E63-E64.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study
AU - Hütter-Krönke, Marie Luise
AU - Fiedler, Walter
AU - Kündgen, Andrea
AU - Krauter, Jürgen
AU - von Lilienfeld-Toal, Marie
AU - Döhner, Hartmut
AU - Schlenk, Richard
N1 - Letter to the Editor
PY - 2019/2
Y1 - 2019/2
KW - Journal Article
U2 - 10.3324/haematol.2018.199794
DO - 10.3324/haematol.2018.199794
M3 - Other (editorial matter etc.)
C2 - 30171028
VL - 104
SP - E63-E64
JO - HAEMATOLOGICA
JF - HAEMATOLOGICA
SN - 0390-6078
IS - 2
ER -